Evaluation of DEAT0217 versus standard of care to compare effectiveness and safety in treating moderate psoriasis in adult patients

Phase 3

Completed

• Conditions: Adult patients diagnosed with mild to moderate psoriasis.; Skin and Connective Tissue Diseases

• Registration Number: ISRCTN28479470
• Lead Sponsor: Devintec SAG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2020-11-11
• Study Start: 2021-12-16
• Last Update Posted: 27 December 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

1. Adult subjects 18 years or older
2. Subjects willing to sign the informed consent
3. Subjects previously diagnosed with mild to moderate plaque psoriasis
4. Subjects willing and able to comply with all clinic visits and study-related procedures

Exclusion Criteria

1. Use of systemic and topical anti psoriatic therapy on the areas within 2 weeks prior to the beginning of the study
2. Concomitant use of systemic anti psoriatic therapy (e.g. methotrexate, biologics, phototherapy)
3. Concomitant use of topical corticotherapy
3. Any dermatological disease that might interfere psoriasis clinical evaluation or bring the subject in danger, or have other serious dermatological disease other than psoriasis
4. Pregnant or breast-feeding women or women planning to become pregnant or breastfeed during the study.
5. Hypersensitivity or allergy to any of the IMP ingredients

Study & Design

• Study Type: Interventional
• Study Design: Not specified